News
ARMP
2.860
-4.67%
-0.140
Why Baudax Bio Shares Are Trading Higher By 60%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga · 01/24 18:11
BRIEF-Armata Pharmaceuticals Inc Entered Into Secured Convertible Credit And Security Agreement With Innoviva Strategic Opportunities Llc
Reuters · 01/10 14:37
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga · 01/04 18:17
BRIEF-Armata Pharmaceuticals Announces Completion Of Its Phase 1B/2A 'Swarm-P.A.' Study Of Inhaled AP-Pa02 In Cystic Fibrosis Subjects With Chronic Pulmonary Pseudomonas Aeruginosa Infection
Reuters · 12/22/2022 13:16
Armata Pharmaceuticals Announces Completion Of Its Phase 1b/2a 'SWARM-P.a.' Study Of Inhaled AP-PA02 In Cystic Fibrosis Subjects With Chronic Pulmonary Pseudomonas aeruginosa Infection
Benzinga · 12/22/2022 13:01
Armata Pharmaceuticals Completes Phase 1b/2a Trial of AP-PA02 to Treat Pseudomonas Aeruginosa Infections
Armata Pharmaceuticals Completes Phase 1b/2a Trial of AP-PA02 to Treat Pseudomonas Aeruginosa Infections
MT Newswires · 12/22/2022 11:25
Why Ambrx Biopharma Shares Are Trading Higher By Over 550%? Here Are 52 Stocks Moving In Friday's Mid-Day Session
Benzinga · 12/09/2022 18:48
Armata Pharmaceuticals, Inc. (ARMP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Armata Pharmaceuticals, Inc. (ARMP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the ne...
Zacks · 12/08/2022 14:55
After Plunging 35.3% in 4 Weeks, Here's Why the Trend Might Reverse for Armata Pharmaceuticals, Inc. (ARMP)
Armata Pharmaceuticals, Inc. (ARMP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates...
Zacks · 11/28/2022 14:35
Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the c...
PR Newswire · 11/28/2022 13:00
Why Richardson Electronics Shares Surged Over 8%; Here Are 55 Biggest Movers From Friday
Benzinga · 11/28/2022 10:09
Here's Why Armata Pharmaceuticals, Inc. (ARMP) Looks Ripe for Bottom Fishing
Armata Pharmaceuticals, Inc. (ARMP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the ne...
Zacks · 11/15/2022 14:55
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday
Benzinga · 11/15/2022 10:19
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Benzinga · 11/14/2022 18:05
Armata Pharmaceuticals GAAP EPS of -$0.24 beats by $0.04, revenue of $1.34M misses by $0.32M
Seekingalpha · 11/09/2022 22:21
Armata Pharmaceuticals Q3 EPS $(0.24) Down From $(0.21) YoY, Sales $1.34M Up From $1.25M YoY
Benzinga · 11/09/2022 22:11
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.
Benzinga · 09/19/2022 05:53
US Stocks Turn Lower; Nasdaq Drops Over 100 Points
U.S. stocks turned lower midway through trading, with the Nasdaq Composite dropping more than 100 points on Thursday.
Benzinga · 09/15/2022 16:04
BRIEF-Armata Pharmaceuticals Announces Second Quarter 2022 Results And Provides Corporate Update
BRIEF-Armata Pharmaceuticals Announces Second Quarter 2022 Results And Provides Corporate Update
Reuters · 08/11/2022 21:20
FDA clears Armata Pharma's application for its treatment for prosthetic joint infection
Armata Pharmaceuticals (NYSE:ARMP) on Monday <a href...
Seekingalpha · 08/01/2022 13:48
More
Webull provides a variety of real-time ARMP stock news. You can receive the latest news about Armata Pharmctcl through multiple platforms. This information may help you make smarter investment decisions.
About ARMP
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using bacteriophage-based technology. It has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The Company is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. It is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The Company is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. It has phage development to target other indications, including non-cystic fibrosis bronchiectasis (NCFB), prosthetic joint infections (PJI) and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.